Exelixis registers Phase 1 pediatric trial of zanzalintinib in solid tumors
Exelixis has posted a new pediatric dose-escalation study of zanzalintinib for relapsed or refractory solid tumors, not yet recruiting.
This week's activity centers on a single new pediatric trial registration for Exelixis.
- Zanzalintinib (also known as XL092), a Phase 1 trial in children and adolescents with relapsed or refractory solid tumors, was newly posted and is not yet recruiting. The study aims to find the pediatric maximum tolerated dose and recommended Phase 2 dose while checking safety and tolerability of zanzalintinib.1 The trial plans to enroll 18 participants (estimated)1 and covers conditions including relapsed or refractory solid tumor, including primary CNS tumors (excluding lymphoma)1. Estimated start is 2026-09-30, with primary completion expected 2028-07-31.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.